Saturday November 21 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

SUGEN

SUGEN is a biopharmaceutical company focused on the discovery and development of small molecule drugs which target specific cellular signal transduction pathways. These signalling pathways are regulated by cell-surface receptors or intracellular signalling molecules known as tyrosine kinases ("TKs"), tyrosine phosphatases ("TPs") and serine-threonine kinases ("STKs"), three of the largest known families of receptors in the body and key regulators of critical cellular functions. Aberrant signalling of TKs, TPs and STKs has been shown to result in a variety of chronic and acute pathological diseases, including cancer and diabetes as well as in dermatologic, ophthalmic, neurologic and immune disorders. The Company believes that compounds designed to target certain kinases and phosphatases and inhibit enzyme activity or prevent the binding of downstream signalling molecules make attractive therapeutic product candidates.


Contact Details:
230 E. Grand Ave
South San Francisco
CA
94080
United States of America
Tel:650 553 8741
Fax:650 553 8348
Email:
WWW:

www.sugen.com/




Loading...

Recent Publications by SUGEN:

Effect of Terminalia arjuna extract on adriamycin-induced DNA damage.
The effect of a bark extract of Terminalia arjuna (TAE) was studied on the...
19th December, 2008
Division of Cancer Biology, Sugen Life Sciences, Tirupati, 517505, AP, Phytother Res. 2008 Sep;22(9):1188-94.
DOI Direct Link
High-performance liquid chromatographic method for determination of reversible isomers of SU5416.
SU5416 shows light-induced reversible geometric isomerism. A simple,...
29th June, 2006
Formulations Research, SUGEN Inc., 230 S. Grand Avenue, South San J Chromatogr A. 2006 Mar 31;1110(1-2):73-80. Epub 2006 Feb 10.
DOI Direct Link
Simultaneous determination of Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone (SU5416) and its interconvertible geometric isomer (SU5886) in rat plasma by LC/MS/MS.
Z-3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-2-indolinone (SU5416) is a...
23rd May, 2006
Department of Bioanalysis and Phamarcokinetcs, Sugen, 230 E. Grand Ave., J Pharm Biomed Anal. 2005 Jul 1;38(3):479-86. Epub 2005 Mar 2.
DOI Direct Link
PAK4 mediates morphological changes through the regulation of GEF-H1.
Precise spatial and temporal regulation of Rho GTPases is required in...
20th September, 2005
SUGEN Incorporated, 230 East Grand Avenue, South San Francisco, CA 94080, J Cell Sci. 2005 May 1;118(Pt 9):1861-72. Epub 2005 Apr 12.
DOI Direct Link
Transcriptional-based screens for pathway-specific, high-throughput target discovery in endothelial cells.
With the sequence of the human genome at hand, target discovery strategies...
13th May, 2005
SUGEN, Inc., J Biomol Screen. 2004 Dec;9(8):704-11.
DOI Direct Link

View more SUGEN research publications.

Press Releases on SUGEN:

BioPortfolio Logo
Longitude Capital Closes $325 Million Life Sciences Fund 8th July, 2008 Longitude Capital
MENLO PARK, Calif., July 8 /PRNewswire/ -- Longitude Capital today announced the closing of its first investment vehicle, Longitude Venture Partners, L.P. (the "Fund"), a $325 million

BioNews Results for SUGEN:

Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
Pharma Live:  Sep 4 2009 12:33PM Matching: sugen
Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
PR Newswire:  Sep 4 2009 12:23PM Matching: sugen
Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
PR Newswire via Yahoo!:  Sep 4 2009 12:17PM Matching: sugen
Kolltan Pharmaceuticals Expands Board of Directors and Senior Executive Team
Pharma Live:  Aug 18 2009 5:50PM Matching: sugen

SUGEN Clinical Trials:

Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

SUGEN Patents:

US Patent No.Title
6706709 Indolinone derivatives as protein kinase/phosphatase inhibitors
6861442 PYK2 and inflammation
6878733 Formulations for pharmaceutical agents ionizable as free acids or free bases
6906093 Indolinone combinatorial libraries and related products and methods for the treatment of disease
6908930 4-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitors

View more SUGEN patents.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 29 individuals from SUGEN using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 558 times since April 2007, the link to the organisation's website has been followed 104 times

Recent Search Terms used to find this page: 230 East Grand Avenue San Francisco CA zip | Sugen Life Sciences | sugen | list sapuser indian companies | sugen venture capital | sugen | sugen logo | SUGEN Inc logo San Fran | sugen | .

Search for more companies in South San Francisco

Search for more companies in CA



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for SUGEN

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.